{"url_path":"/sec/amix/10-k/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-K/A","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1617867/0001437749-26-020686-index.html","accession_number":"0001437749-26-020686","cik":"0001617867","ticker":"AMIX","issuer_name":"Autonomix Medical, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1617867/0001437749-26-020686-index.html","primary_entity_key":"0001617867","primary_entity_name":"Autonomix Medical, Inc."},"word_count":1183,"has_tables":true,"body_markdown":"amix20260331c_10ka.htm\n\nFY\n2025\n--03-31\ntrue\n0001617867\n\n00016178672025-04-012026-03-31\nthunderdome:item\nxbrli:shares\n00016178672026-06-10\niso4217:USD\n00016178672025-09-30\n\n \n\n[Table of Contents](#toc)\n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**WASHINGTON, D.C., 20549**\n\n \n\n**FORM 10-K/A**\n\n**(Amendment No. 1)**\n\n \n\n☒\n\n**ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For the fiscal year ended** **March 31, 2026**\n\n**OR**\n\n☐\n\n**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\nFor the transition period from _________________ to ___________________\n\n \n\n**Commission File Number:** **001-41940**\n\n \n\n**AUTONOMIX MEDICAL, INC.**\n\n**(Exact Name of Registrant as Specified in its Charter)**\n\n**Delaware**\n\n \n\n**47-1607810**\n\n**(State or Other Jurisdiction of**\n\n \n\n**(I.R.S. Employer Identification No.)**\n\n**Incorporation or Organization)**\n\n \n \n\n**21 Waterway Avenue, Suite 300**\n\n**The Woodlands, Texas 77380**\n\n**(Address of Principal Executive Offices) (Zip Code)**\n\n**Registrant**’**s Telephone Number, including Area Code:**\n\n**(713) 588-6150**\n\n \n\nSecurities Registered Pursuant to Section 12(b) of the Act:\n\nTitle of each class\n\nTrading Symbol(s)\n\nName of each exchange on which registered\n\n**Common Stock, $0.001 par value**\n\n**AMIX**\n\n**The Nasdaq Stock Market**\n\n \n\n**Securities Registered Pursuant to Section** **12(g) of the Act:**\n\n \n\n**None**\n\n**(Title of Class)**\n\n \n\nIndicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☐    No   ☒\n\n \n\nIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ☐    No   ☒\n\n \n\n \n\n[Table of Contents](#toc)\n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods as the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No   ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No   ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (check one)\n\n \n\nLarge accelerated filer \n\n☐\n\n \n\nAccelerated filer \n\n☐\n\n \n\nNon-accelerated filer \n\n☒\n\n \n\nSmaller reporting company  \n\n☒\n\n \n \n \n \n \n \n \n \n \n\nEmerging growth company\n\n☒\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) by the registered public accounting firm that prepared or issued its audit report.  ☐\n\n \n\n \n\n[Table of Contents](#toc)\n\n \n\nIf securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☒\n\n \n\nIndicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ☐    No   ☒\n\n \n\nThe aggregate market value of the registrant’s voting equity held by non-affiliates of the registrant, computed by reference to the price at which the common stock was last sold as of the last business day of the registrant’s most recently completed second fiscal quarter, was $6,307,279. In determining the market value of the voting equity held by non-affiliates, securities of the registrant beneficially owned by directors, officers and 10% or greater shareholders of the registrant have been excluded. This determination of affiliate status is not necessarily a conclusive determination for other purposes.\n\n \n\nThe number of shares of the registrant’s common stock outstanding as of June 10, 2026 was 11,409,344.\n\n \n\n**DOCUMENTS INCORPORATED BY REFERENCE**\n\n \n\nNone.\n\n \n\n \n\n[Table of Contents](#toc)\n\n \n\n**EXPLANATORY NOTE**\n\n \n\nAutonomix Medical, Inc. is filing this Amendment No. 1 on Form 10-K/A, or this Amendment No. 1 to our Annual Report on Form 10-K for the fiscal year ended March 31, 2026, or the Original 10-K, originally filed with the U.S. Securities and Exchange Commission, or SEC, on May 27, 2026, or Original Filing Date, solely for the purpose of including the information required by Items 10 through 14 of Part III of Form 10-K. This information was previously omitted from the Original 10-K in reliance on General Instruction G(3) to Form 10-K, which permits the information in the above referenced items to be incorporated in the Original 10-K by reference from our definitive proxy statement so long as such proxy statement is filed no later than 120 days after our fiscal year-end. We are filing this Amendment No. 1 to include the Part III information in the Original Form 10-K.\n\n \n\nThis Amendment No. 1 amends and restates in their entirety Items 10 through 14 of the Original 10-K. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, this Amendment No. 1 also contains new certifications by the principal executive officer and the principal financial officer as required by Section 302 of the Sarbanes-Oxley Act of 2002. Accordingly, Item 15 of Part IV is amended to include the currently dated certifications of our principal executive officer and principal financial officer as exhibits. Because no financial statements have been included in this Amendment No. 1 and this Amendment No. 1 does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4 and 5 of the certifications have been omitted. In addition, because no financial statements are included in this Amendment No. 1, new certifications of our principal executive officer and principal financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 are not required to be included with Amendment No. 1.\n\n \n\nExcept as described above, no other changes have been made to the Original 10-K. The Original 10-K continues to speak as of the date of the Original 10-K, and we have not updated the disclosures contained therein to reflect any events that have occurred as of a date subsequent to the date of the Original 10-K. Accordingly, this Amendment No. 1 should be read in conjunction with the Original 10-K. Defined terms used, but not defined, herein have the meanings ascribed to them in the Original 10-K.\n\n \n\nUnless stated otherwise, references in this Amendment No. 1 to “Autonomix Medical,” or “the Company”, “we”, “our” and “us” are used herein to refer to Autonomix Medical, Inc.\n\n \n\n \n\n[Table of Contents](#toc)\n\n \n\n \n\n \n\n \n\n**TABLE OF CONTENTS**\n\n \n\n[PART III](#partiii)"}